Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CORAL
NCT06397768Phase 3Terminated
- Sponsor
- Sanofi
- Start
- May 2024
- Primary completion
- Sep 2025
- Modality
- Live Attenuated Vaccines
- Countries
- 3
01
Overview
A Phase 3 trial of RSVt vaccine in respiratory syncytial virus infection (RSV), sponsored by Sanofi. Started May 2024; status: terminated.
02
Drugs
RSVt vaccine
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT06397768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06397768.